<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809731</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-NTW-SER-2008/1</org_study_id>
    <nct_id>NCT00809731</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment</brief_title>
  <acronym>QTP NIS</acronym>
  <official_title>A Naturalistic Observational Study to Evaluate Efficacy of 2nd-generation Antipsychotics and Remission Status for Patients With Schizophrenia / Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate under routine clinical setting the efficacy and&#xD;
      remission status from treatment of 2nd-generation antipsychotic in patients who is upon acute&#xD;
      episode or not achieving remission under regular treatment from schizophrenia/schizoaffective&#xD;
      disorder. This study will collect in real-life practice the severity of schizophrenia by&#xD;
      Clinical Global Impression (CGI), also evaluate the criteria of schizophrenia remission&#xD;
      applying 8 items of Positive and Negative Syndrome Scale (PANSS) from Andresen working group,&#xD;
      the Montgomery and Asberg Depression Rating Scale (MADRS), and the Global Assessment of&#xD;
      Functioning Scale (GAF). Side effect of movement disorder will be evaluated by Drug Induced&#xD;
      Extrapyramidal Symptoms Scale (DIEPSS). Tolerability for treatment will be monitored by&#xD;
      documenting spontaneous reports on adverse events as well as change in body weight.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CGI-Severity of illness (CGI-SI)</measure>
    <time_frame>Visit 1(Day 0), 2(Day 3), 3(Week 1), 4(Week 2), 5(Week 4)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI-Degree of change (CGI-DC)</measure>
    <time_frame>Visit 2(Day 3), 3(Week 1), 4(Week 2), 5(Week 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MADRS, GAF, DIEPSS</measure>
    <time_frame>Visit 1(Day 0), 2(Day 3), 3(Week 1), 4(Week 2), 5(Week 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission status</measure>
    <time_frame>Visit 1(Day 0), 5(Week 4)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">490</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Observational Group</arm_group_label>
    <description>All commercially available 2nd-generation antipsychotic with an indication of treating schizophrenia will be prescribed by the physician according to normal practices</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute episode (first or relapse), or upon revisit and identified not&#xD;
        achieving remission of schizophrenia or schizoaffective disorder (according to remission&#xD;
        criteria of schizophrenia)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with acute episode (first or relapse), or upon revisit and identified not&#xD;
             achieving remission of schizophrenia or schizoaffective disorder (according to&#xD;
             remission criteria of schizophrenia)&#xD;
&#xD;
          -  Male or female aged between 18 and 65 years&#xD;
&#xD;
          -  Patients recruited from both in-patient and out-patient clinics&#xD;
&#xD;
          -  Patients who are cooperative, by judgment from investigators, and the use of oral&#xD;
             antipsychotic considered adequate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Patients who, in the opinion of the investigator, pose an imminent risk of suicide or&#xD;
             a danger to self or others&#xD;
&#xD;
          -  Known intolerance, lack of response, or contraindication to prescribed atypical&#xD;
             antipsychotic, as judged by the investigator&#xD;
&#xD;
          -  Administration of a depot antipsychotic injection within one dosing interval (for the&#xD;
             depot) before enrolment and patients prescribed with clozapine within 3 months prior&#xD;
             to enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuan-Hwa Chou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changhua-Lugang</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung-Niosong</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung-Sanmin</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung-Yanchao</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miaoli-Toufen</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miaoli</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung-Beitun</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung-Shalu</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei-Banciao</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei-Datong</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei-Shilin</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei-Shipai</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei-Xindian</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <last_update_submitted>December 8, 2010</last_update_submitted>
  <last_update_submitted_qc>December 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robin Meng/Marketing Company Medical Director</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Schizophrenia remission status by 8-item PANSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

